InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | 2026-03-16 | Adamson Philip B. | Chief Medical Officer | Sale | 1,262 | $7.90 | $10K | 61.6K | View ↗ | |
| 2026-03-02 | 2026-03-03 | Hykes Kevin | Director & PRES & CEO | Sale | 7,763 | $7.90 | $61K | 284.2K | View ↗ | |
| 2026-03-02 | 2026-03-03 | VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER | Sale | 1,284 | $7.90 | $10K | 60.6K | View ↗ | |
| 2026-03-02 | 2026-03-03 | OASHEIM JARED | CHIEF FINANCIAL OFFICER | Sale | 1,744 | $7.90 | $14K | 96.7K | View ↗ | |
| 2026-03-02 | 2026-03-03 | John Robert Allen | Chief Revenue Officer | Sale | 3,964 | $7.90 | $31K | 86.0K | View ↗ |
No annual data found.
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026